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http://dx.doi.org/10.1016/j.stem.2013.07.013When the first human induced Pluripotent
StemCells (iPSCs) were generated (Taka-
hashi et al., 2007), the expectations
surrounding the development of human
SCNT methodologies for personalized
medicine were rapidly wiped out. A recent
report by Mitalipov and colleagues
demonstrating the generation of human
somatic cell nuclear transfer-derived
embryonic stem cells (SCNT-ESCs)
opens this long-standing debate once
again, now with the added question of
whether SCNT-ESCs will prove to be
a better source than iPSCs for personal-
ized regenerative medicine (Tachibana
et al., 2013). To resolve this debate,
researchers will need to address issues
that, among others, include (1) the repro-
ducibility, simplification, and expansion
of SCNT technologies; (2) the potential
of SCNT-ESCs for proper cell-type-spe-
cific differentiation and engraftment; (3)
the role that maternal mitochondria might
play in SCNT-ESCs; (4) the safety con-
cerns inherently related to the use of
pluripotent cells; and (5) the possibility
that distinct molecular signatures underlie
different pluripotent states.
As is the case for iPSC derivation,
somatic nuclear age, disease status,
mutational load, and specific cell type
may influence epigenetic plasticity
and potentially compromise SCNT-ESC
derivation and utilization. SCNT should
thus be expanded to include comparative
analyses of a variety of cell types
from healthy, diseased, and aged indiv-
iduals (the report by Mitalipov and col-
leagues focused exclusively on nuclei
derived from fetal fibroblasts as well as
those derived from a young patient with
Leigh Syndrome). Regardless of the
donor cell type, oocyte quality seems
to have a determining role for suc-
cessful SCNT. Molecular signatures
defining oocyte quality, and accordingly
their reprogramming potential, will
need to be determined to enhanceSCNT-ESC reproducibility, uniformity,
and efficiency.
It is not clear whether SCNT-ESCs will,
similar to iPSCs, face issues in terms of
altered differentiation potential and
immature phenotypes (Robinton and Da-
ley, 2012). Abnormal migration and/or
integration of differentiated cells derived
from iPSCs into the target host tissue
may eventually compromise functionality.
These abnormalities could be due to
incomplete resetting of the epigenome,
acquisition of aberrant methylation pat-
terns, and/or inefficient differentiation
protocols. Since it is argued that SCNT-
ESCs may display a more complete
resetting of the epigenome, as SCNT
reprogramming involves the establish-
ment of embryonic imprinting patterns,
it would be of enormous interest to
determine whether and if so, how,
SCNT-ESCs are functionally superior to
iPSCs under the same differentiation
conditions. Interestingly, a recent report
by Hayashi and colleagues has indicated
that both iPSCs and allogeneic ESCs
derived from mice are capable of gener-
ating viable oocytes that result in normal
offspring (Hayashi et al., 2012). Whereas
the findings by Hayashi and colleagues
argue that both types of pluripotent
cells present comparable differentiation
potential, it is well accepted that
murine and human PSCs present impor-
tant differences that warrant further
investigation.
A potential concern related to SCNT-
ESCs involves heteroplasmy, the pres-
ence of mitochondrial DNA (mtDNA)
from dual origins. The mtDNA carried
over during nuclear transfer may trigger
immunogenicity, a controversial issue
surrounding the use of iPSCs (Yamanaka,
2012). Although this issue has been
debated, recent data support claims that
murine SCNT-ESCs lack immunogenicity.
For example, Craven and colleagues re-
ported that donor mitochondria fall belowCell Stem Cell 1the immune system’s detection level
based on DNA amplification techniques
(Craven et al., 2010). However, whether
this will be the case when differentiated
humanSCNT-ESCs are exposed to actual
immune cell recognition remains un-
known. Moreover, due to the high degree
of sequence variability of human mtDNA,
changesmay occur in the molecular inter-
actions between nuclear and mito-
chondrial genomes and thus alter cellular
function. If maternal mitochondria and
reprogrammed somatic nuclei are able
to reestablish proper interaction, SCNT-
ESCs could constitute a new approach
to treating mitochondrial diseases pre-
sent in homoplasmy. Yet, since most
mitochondrial diseases are heteroplas-
mic, other approaches, such as spindle
transfer, isogenic correction in iPSCs,
and induction of heteroplasmic shift,
might be needed.
Safety concerns constitute a major
issue associated with the use of PSCs.
With the continuous improvement of non-
integrative approaches for iPSC genera-
tion, the remaining safety issues relate to
the potential transplantation of residual
PSCs or the possibility of in vivo dediffer-
entiation. Interestingly, dedifferentiation
has been shown to underlie both cell
transformation and reprogramming to
iPSCs, and the presence of ‘‘stem cell’’
signatures in cancer cells has been corre-
lated with increasedmalignancy (Visvader
and Lindeman, 2012). Along this line, a
major difference between both reprog-
ramming processes is that, contrary to
SCNT, iPSC generation is a long process
influenced by cell proliferation. This
extended timeframe opens the possibility
that spontaneous mutations contributing
to the dedifferentiation and/or enhanced
proliferation are positively selected during
reprogramming to iPSCs. If proven to be
the case, selection during iPSC reprog-
ramming would be analogous to what
has been described during tumorigenesis3, August 1, 2013 ª2013 Elsevier Inc. 141
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Letterand suggests that SCNT technologies
may have the advantage of reducing the
risk for oncogenic transformation. Addi-
tionally, reprogramming by SCNT or
iPSC approaches will most probably
generate differences at the epigenetic
and/or genetic level, which may affect
genetic instability and potential for malig-
nant transformation. These questions still
await experimental answers.
Controversy remains as to whether
iPSCs are molecularly identical to ESCs
or if they represent a distinct pluripotent
state (Yamanaka, 2012). To date, reprog-
ramming has been described to occur by
(1) factors present in the oocyte (SCNT),
(2) factors typical of ESCs derived from
the inner cells mass of the blastocyst
(iPSCs), and more recently, (3) factors
involved in lineage specification (iPSCs)
(Shu et al., 2013; Montserrat et al.,
2013). This indicates that different paths
to pluripotency can be used and extends
the initial question about which cell
source, SCNT-ESCs, iPSCs, or ESCs,
would be most suitable for cell therapy.
Noticeably, whereas ESCs from cloned
embryos are virtually indistinguishable
from those derived from fertilized ones
by microarray analysis (Brambrink et al.,
2006); higher resolution techniques and142 Cell Stem Cell 13, August 1, 2013 ª2013analysis of noncoding regions might high-
light previously unexpected differences.
Identification of different molecular signa-
tures will contribute to the development of
better reprogramming strategies and may
lead to the elucidation of the best cell
source for clinical applications.
Despite some criticisms and unan-
swered questions on the practicality and
utility of SNCT-ESCs, human SCNT tech-
nologies will probably contribute to the
identification of novel reprogramming
factors, which in turn may lead to more
efficient generation and higher quality
iPSCs. Paradoxically, identification of
mechanisms facilitating iPSC reprogram-
ming stemming from an increased under-
standing of human SCNTmight eventually
contribute to the disuse of SCNT-ESCs,
which will always face ethical concerns
that other reprogramming approaches
avoid. Regardless of which source is
deemed most useful for cell therapy, the
testing and comparison of SCNT-ESCs
with current PSCs will provide new
vistas and opportunities for the study of
the mechanisms underlying repro-
gramming. The hope is that these studies
may eventually help the development
of effective and safe stem-cell-based
therapies.Elsevier Inc.REFERENCES
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